An Overview of Gastrointestinal Dysfunction in Parkinsonian Syndromes

Abstract

Gastrointestinal (GI) dysfunction is a common nonmotor symptom in Parkinson's disease (PD) as well as other parkinsonian syndromes and may precede the onset of motor symptoms by decades. Involvement of all segments of the GI tract can lead to altered responses to medications and worsened quality of life for patients. While some GI symptoms occur in isolation, others overlap. Therefore, understanding the changes in different segments of the GI tract and how they relate to altered responses to PD treatment can guide both diagnostic and pharmacological interventions. Gut microbiota plays a critical role in immune activity and modulation of the enteric and central nervous systems. Understanding this bidirectional relationship helps to elucidate the pathogenesis of neurodegeneration. This review will describe the current understanding of how GI dysfunction develops in parkinsonian syndromes, common symptoms in PD and related disorders, and available treatments.

Keywords

Parkinson's disease - gastrointestinal dysfunction - atypical parkinsonism - gut - parkinsonism

Publikationsverlauf

Artikel online veröffentlicht:
13. September 2023

• References

• 1 Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol 2016; 79 (06) 940-949
• 2 Hilton D, Stephens M, Kirk L. et al. Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. Acta Neuropathol 2014; 127 (02) 235-241
• 3 Liu B, Fang F, Pedersen NL. et al. Vagotomy and Parkinson disease: a Swedish register-based matched-cohort study. Neurology 2017; 88 (21) 1996-2002
• 4 Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) 2003; 110 (05) 517-536
• 5 Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007; 33 (06) 599-614
• 6 Adler CH, Beach TG. Neuropathological basis of nonmotor manifestations of Parkinson's disease. Mov Disord 2016; 31 (08) 1114-1119
• 7 Beach TG, Adler CH, Sue LI. et al. Vagus nerve and stomach synucleinopathy in Parkinson's disease, incidental Lewy body disease, and normal elderly subjects: evidence against the “body-first” hypothesis. J Parkinsons Dis 2021; 11 (04) 1833-1843
• 8 Safarpour D, Sharzehi K, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Drugs 2022; 82 (02) 169-197
• 9 Borghammer P, Van Den Berge N. Brain-first versus gut-first Parkinson's Disease: A Hypothesis. J Parkinsons Dis 2019; 9 (s2): S281-S295
• 10 Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: the unseen majority. Proc Natl Acad Sci U S A 1998; 95 (12) 6578-6583
• 11 Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006; 124 (04) 837-848
• 12 Pascale A, Marchesi N, Marelli C. et al. Microbiota and metabolic diseases. Endocrine 2018; 61 (03) 357-371
• 13 Varesi A, Pierella E, Romeo M. et al. The potential role of gut microbiota in Alzheimer's disease: from diagnosis to treatment. Nutrients 2022; 14 (03) 668
• 14 Cattaneo A, Cattane N, Galluzzi S. et al; INDIA-FBP Group. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging 2017; 49: 60-68
• 15 Gerhardt S, Mohajeri MH. Changes of colonic bacterial composition in Parkinson's disease and other neurodegenerative diseases. Nutrients 2018; 10 (06) 708
• 16 Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne) 2020; 11: 25
• 17 Hirayama M, Ohno K. Parkinson's disease and gut microbiota. Ann Nutr Metab 2021; 77 (Suppl. 02) 28-35
• 18 Grathwohl SA, Steiner JA, Britschgi M, Brundin P. Mind the gut: secretion of α-synuclein by enteric neurons. J Neurochem 2013; 125 (04) 487-490
• 19 Sampson TR, Challis C, Jain N. et al. A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice. eLife 2020; 9: e53111
• 20 Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol 2015; 21 (37) 10609-10620
• 21 Sampson TR, Debelius JW, Thron T. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 2016; 167 (06) 1469-1480.e12
• 22 Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 2012; 27 (06) 716-719
• 23 Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24 (02) 197-211
• 24 Keshavarzian A, Green SJ, Engen PA. et al. Colonic bacterial composition in Parkinson's disease. Mov Disord 2015; 30 (10) 1351-1360
• 25 Kelly LP, Carvey PM, Keshavarzian A. et al. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord 2014; 29 (08) 999-1009
• 26 Engen PA, Dodiya HB, Naqib A. et al. The potential role of gut-derived inflammation in multiple system atrophy. J Parkinsons Dis 2017; 7 (02) 331-346
• 27 Kang DW, Adams JB, Gregory AC. et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 2017; 5 (01) 10
• 28 Kang DW, Adams JB, Coleman DM. et al. Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Sci Rep 2019; 9 (01) 5821
• 29 Yin J, Liao SX, He Y. et al. Dysbiosis of gut microbiota with reduced trimethylamine-N-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack. J Am Heart Assoc 2015; 4 (11) e002699
• 30 Bogiatzi C, Gloor G, Allen-Vercoe E. et al. Metabolic products of the intestinal microbiome and extremes of atherosclerosis. Atherosclerosis 2018; 273: 91-97
• 31 Tremlett H, Fadrosh DW, Faruqi AA. et al; US Network of Pediatric MS Centers. Gut microbiota in early pediatric multiple sclerosis: a case-control study. Eur J Neurol 2016; 23 (08) 1308-1321
• 32 Cryan JF, O'Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol 2020; 19 (02) 179-194
• 33 Nuzum ND, Loughman A, Szymlek-Gay EA, Hendy A, Teo WP, Macpherson H. Gut microbiota differences between healthy older adults and individuals with Parkinson's disease: a systematic review. Neurosci Biobehav Rev 2020; 112: 227-241
• 34 Wang Q, Luo Y, Ray Chaudhuri K, Reynolds R, Tan EK, Pettersson S. The role of gut dysbiosis in Parkinson's disease: mechanistic insights and therapeutic options. Brain 2021; 144 (09) 2571-2593
• 35 Bhattacharyya D, Mohite GM, Krishnamoorthy J. et al. Lipopolysaccharide from gut microbiota modulates α-synuclein aggregation and alters its biological function. ACS Chem Neurosci 2019; 10 (05) 2229-2236
• 36 Bhattarai Y. Microbiota-gut-brain axis: interaction of gut microbes and their metabolites with host epithelial barriers. Neurogastroenterol Motil 2018; 30 (06) e13366
• 37 Klann EM, Dissanayake U, Gurrala A. et al. The gut-brain axis and its relation to Parkinson's disease: a review. Front Aging Neurosci 2022; 13: 782082
• 38 Nishiwaki H, Ito M, Ishida T. et al. Meta-analysis of gut dysbiosis in Parkinson's disease. Mov Disord 2020; 35 (09) 1626-1635
• 39 Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis 2021; 7 (01) 27
• 40 Sun MF, Zhu YL, Zhou ZL. et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun 2018; 70: 48-60
• 41 Lubomski M, Xu X, Holmes AJ, Yang JYH, Sue CM, Davis RL. The impact of device-assisted therapies on the gut microbiome in Parkinson's disease. J Neurol 2022; 269 (02) 780-795
• 42 Lubomski M, Xu X, Holmes AJ. et al. The gut microbiome In Parkinson's disease: a longitudinal study of the impacts on disease progression and the use of device-assisted therapies. Front Aging Neurosci 2022; 14: 875261
• 43 Makaroff L, Gunn A, Gervasoni C, Richy F. Gastrointestinal disorders in Parkinson's disease: prevalence and health outcomes in a US claims database. J Parkinsons Dis 2011; 1 (01) 65-74
• 44 Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003; 2 (02) 107-116
• 45 Abbott RD, Petrovitch H, White LR. et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001; 57 (03) 456-462
• 46 Verhoeff MC, Lobbezoo F, van Leeuwen AM, Schuller AA, Koutris M. Oral health-related quality of life in patients with Parkinson's disease. J Oral Rehabil 2022; 49 (04) 398-406
• 47 John TK, Vasanthy B, Madhavanpillai BR, Gomez MS, Kuriakose R. Does parkinsonism affect periodontal health? A cross-sectional study in a tertiary hospital. J Indian Soc Periodontol 2021; 25 (06) 538-543
• 48 Barbe AG, Bock N, Derman SH, Felsch M, Timmermann L, Noack MJ. Self-assessment of oral health, dental health care and oral health-related quality of life among Parkinson's disease patients. Gerodontology 2017; 34 (01) 135-143
• 49 Fukayo S, Nonaka K, Shimizu T, Yano E. Oral health of patients with Parkinson's disease: factors related to their better dental status. Tohoku J Exp Med 2003; 201 (03) 171-179
• 50 Nakayama Y, Washio M, Mori M. Oral health conditions in patients with Parkinson's disease. J Epidemiol 2004; 14 (05) 143-150
• 51 Hanaoka A, Kashihara K. Increased frequencies of caries, periodontal disease and tooth loss in patients with Parkinson's disease. J Clin Neurosci 2009; 16 (10) 1279-1282
• 52 Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2015; 14 (06) 625-639
• 53 Nicaretta DH, de Rosso AL, Maliska C, Costa MM. Scintigraphic analysis of the parotid glands in patients with sialorrhea and Parkinson's disease. Parkinsonism Relat Disord 2008; 14 (04) 338-341
• 54 Srivanitchapoom P, Pandey S, Hallett M. Drooling in Parkinson's disease: a review. Parkinsonism Relat Disord 2014; 20 (11) 1109-1118
• 55 Kalf JG, Munneke M, van den Engel-Hoek L. et al. Pathophysiology of diurnal drooling in Parkinson's disease. Mov Disord 2011; 26 (09) 1670-1676
• 56 South AR, Somers SM, Jog MS. Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study. Neurology 2010; 74 (15) 1198-1202
• 57 Marks L, Turner K, O'Sullivan J, Deighton B, Lees A. Drooling in Parkinson's disease: a novel speech and language therapy intervention. Int J Lang Commun Disord 2001; 36 (Suppl): 282-287
• 58 Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002; 17 (06) 1318-1320
• 59 Thomsen TR, Galpern WR, Asante A, Arenovich T, Fox SH. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007; 22 (15) 2268-2273
• 60 Arbouw ME, Movig KL, Koopmann M. et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 2010; 74 (15) 1203-1207
• 61 Seppi K, Ray Chaudhuri K, Coelho M. et al; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord 2019; 34 (02) 180-198
• 62 Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006; 21 (05) 704-707
• 63 Jost WH, Friedman A, Michel O. et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology 2019; 92 (17) e1982-e1991
• 64 Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord 2012; 27 (02) 219-226
• 65 Rajaei A, Ashtari F, Azargoon SA. et al. The association between saliva control, silent saliva penetration, aspiration, and videofluoroscopic findings in Parkinson's disease patients. Adv Biomed Res 2015; 4: 108
• 66 Cereda E, Cilia R, Klersy C. et al. Swallowing disturbances in Parkinson's disease: a multivariate analysis of contributing factors. Parkinsonism Relat Disord 2014; 20 (12) 1382-1387
• 67 Mehanna R, Jankovic J. Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord 2010; 16 (10) 628-638
• 68 Potulska A, Friedman A, Królicki L, Spychala A. Swallowing disorders in Parkinson's disease. Parkinsonism Relat Disord 2003; 9 (06) 349-353
• 69 Su A, Gandhy R, Barlow C, Triadafilopoulos G. Clinical and manometric characteristics of patients with Parkinson's disease and esophageal symptoms. Dis Esophagus 2017; 30 (04) 1-6
• 70 Taira K, Fujiwara K, Fukuhara T, Koyama S, Morisaki T, Takeuchi H. Evaluation of the pharynx and upper esophageal sphincter motility using high-resolution pharyngeal manometry for Parkinson's disease. Clin Neurol Neurosurg 2021; 201: 106447
• 71 Castell JA, Johnston BT, Colcher A, Li Q, Gideon RM, Castell DO. Manometric abnormalities of the oesophagus in patients with Parkinson's disease. Neurogastroenterol Motil 2001; 13 (04) 361-364
• 72 Heetun ZS, Quigley EM. Gastroparesis and Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2012; 18 (05) 433-440
• 73 Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013; 108 (01) 18-37 , quiz 38
• 74 Heimrich KG, Jacob VYP, Schaller D, Stallmach A, Witte OW, Prell T. Gastric dysmotility in Parkinson's disease is not caused by alterations of the gastric pacemaker cells. NPJ Parkinsons Dis 2019; 5: 15
• 75 Unger MM, Möller JC, Mankel K. et al. Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease?. J Neurol 2011; 258 (06) 982-990
• 76 Kurlan R, Rothfield KP, Woodward WR. et al. Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility. Neurology 1988; 38 (03) 419-421
• 77 Robertson DR, Renwick AG, Wood ND. et al. The influence of levodopa on gastric emptying in man. Br J Clin Pharmacol 1990; 29 (01) 47-53
• 78 Hardoff R, Sula M, Tamir A. et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 2001; 16 (06) 1041-1047
• 79 Pfeiffer RF, Isaacson SH, Pahwa R. Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. Parkinsonism Relat Disord 2020; 76: 63-71
• 80 Buffery PJ, Strother RM. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. N Z Med J 2015; 128 (1416) 66-74
• 81 Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord 2018; 33 (03) 372-390
• 82 Asai H, Udaka F, Hirano M. et al. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease. Parkinsonism Relat Disord 2005; 11 (08) 499-502
• 83 Pinyopornpanish A, Teeyasoontranon PKW, Angkurawaranon C, Thongsawat S. The effect of prucalopride on gastric emptying in Parkinson's disease patients, a pilot randomized, open-label study. Digestive Syst 2017; 1 (01) 1-6
• 84 Gil RA, Hwynn N, Fabian T, Joseph S, Fernandez HH. Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients. Parkinsonism Relat Disord 2011; 17 (04) 285-287
• 85 Heckert J, Sankineni A, Hughes WB, Harbison S, Parkman H. Gastric electric stimulation for refractory gastroparesis: a prospective analysis of 151 patients at a single center. Dig Dis Sci 2016; 61 (01) 168-175
• 86 Arai E, Arai M, Uchiyama T. et al. Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease. Brain 2012; 135 (Pt 5): 1478-1485
• 87 Antonini A, Ursino G, Calandrella D, Bernardi L, Plebani M. Continuous dopaminergic delivery in Parkinson's disease. J Neurol 2010; 257 (Suppl. 02) S305-S308
• 88 Ricci C, Holton J, Vaira D. Diagnosis of Helicobacter pylori: invasive and non-invasive tests. Best Pract Res Clin Gastroenterol 2007; 21 (02) 299-313
• 89 Fasano A, Bove F, Gabrielli M. et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013; 28 (09) 1241-1249
• 90 Shen X, Yang H, Wu Y, Zhang D, Jiang H. Meta-analysis: association of Helicobacter pylori infection with Parkinson's diseases. Helicobacter 2017; (e-pub ahead of print)
• 91 Niehues M, Hensel A. In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinical differences in bioavailability?. J Pharm Pharmacol 2009; 61 (10) 1303-1307
• 92 Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord 2008; 23 (12) 1696-1700
• 93 Pierantozzi M, Pietroiusti A, Brusa L. et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 2006; 66 (12) 1824-1829
• 94 Hashim H, Azmin S, Razlan H. et al. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease. PLoS One 2014; 9 (11) e112330
• 95 Tan AH, Lim SY, Mahadeva S. et al. Helicobacter pylori eradication in Parkinson's disease: a randomized placebo-controlled trial. Mov Disord 2020; 35 (12) 2250-2260
• 96 Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol 2010; 257 (Suppl. 02) S253-S261
• 97 Pfeiffer R. Beyond here be dragons: SIBO in Parkinson's disease. Mov Disord 2013; 28 (13) 1764-1765
• 98 Bohm M, Siwiec RM, Wo JM. Diagnosis and management of small intestinal bacterial overgrowth. Nutr Clin Pract 2013; 28 (03) 289-299
• 99 Gasbarrini A, Lauritano EC, Gabrielli M. et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 2007; 25 (03) 237-240
• 100 Sroka N, Rydzewska-Rosołowska A, Kakareko K, Rosołowski M, Głowińska I, Hryszko T. Show me what you have inside-the complex interplay between SIBO and multiple medical conditions—a systematic review. Nutrients 2022; 15 (01) 90
• 101 Erdogan A, Rao SS, Gulley D, Jacobs C, Lee YY, Badger C. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 2015; 27 (04) 481-489
• 102 Barbara G, Stanghellini V, Brandi G. et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005; 100 (11) 2560-2568
• 103 Quigley EM. Microflora modulation of motility. J Neurogastroenterol Motil 2011; 17 (02) 140-147
• 104 Tan AH, Mahadeva S, Thalha AM. et al. Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism Relat Disord 2014; 20 (05) 535-540
• 105 Gabrielli M, Bonazzi P, Scarpellini E. et al. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2011; 26 (05) 889-892
• 106 Safarpour D, Brumbach BH, Arena M. et al. Gastrointestinal motility and response to levodopa in Parkinson's disease: a proof-of-concept study. Mov Disord 2022; 37 (10) 2153-2158
• 107 Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008; 53 (06) 1443-1454
• 108 Bushyhead D, Quigley EM. Small intestinal bacterial overgrowth. Gastroenterol Clin North Am 2021; 50 (02) 463-474
• 109 Matsumoto T, Iida M, Hirakawa M. et al. Breath hydrogen test using water-diluted lactulose in patients with gastrointestinal amyloidosis. Dig Dis Sci 1991; 36 (12) 1756-1760
• 110 Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011; 60 (03) 334-340
• 111 Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: small intestinal bacterial overgrowth. Am J Gastroenterol 2020; 115 (02) 165-178
• 112 Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006; 73 (Suppl. 01) 13-27
• 113 Pimentel M, Lembo A, Chey WD. et al; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364 (01) 22-32
• 114 Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994; 14 (02) 51-56
• 115 Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017; 45 (05) 604-616
• 116 Vizcarra JA, Wilson-Perez HE, Fasano A, Espay AJ. Small intestinal bacterial overgrowth in Parkinson's disease: tribulations of a trial. Parkinsonism Relat Disord 2018; 54: 110-112
• 117 Spinucci G, Guidetti M, Lanzoni E, Pironi L. Endogenous ethanol production in a patient with chronic intestinal pseudo-obstruction and small intestinal bacterial overgrowth. Eur J Gastroenterol Hepatol 2006; 18 (07) 799-802
• 118 Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for preventing and treating small intestinal bacterial overgrowth: a meta-analysis and systematic review of current evidence. J Clin Gastroenterol 2017; 51 (04) 300-311
• 119 Chang BW, Rezaie A. Irritable bowel syndrome-like symptoms following fecal microbiota transplantation: a possible donor-dependent complication. Am J Gastroenterol 2017; 112 (01) 186-187
• 120 Tan X, Johnson S. Fecal microbiota transplantation (FMT) for C. difficile infection, just say ‘No’. Anaerobe 2019; 60: 102092
• 121 Martinez-Martin P, Schapira AH, Stocchi F. et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007; 22 (11) 1623-1629
• 122 Chaudhuri KR, Martinez-Martin P, Schapira AH. et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006; 21 (07) 916-923
• 123 Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA 2020; 323 (06) 548-560
• 124 Adams-Carr KL, Bestwick JP, Shribman S, Lees A, Schrag A, Noyce AJ. Constipation preceding Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2016; 87 (07) 710-716
• 125 Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB. MDS Task Force on the Definition of Parkinson's Disease. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord 2019; 34 (10) 1464-1470
• 126 Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Characterization of swallowing and defecation in Parkinson's disease. Am J Gastroenterol 1994; 89 (01) 15-25
• 127 Camilleri M, Brandler J. Refractory constipation: how to evaluate and treat. Gastroenterol Clin North Am 2020; 49 (03) 623-642
• 128 Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100 (01) 232-242
• 129 Rao SS, Rattanakovit K, Patcharatrakul T. Diagnosis and management of chronic constipation in adults. Nat Rev Gastroenterol Hepatol 2016; 13 (05) 295-305
• 130 Bonapace ES, Maurer AH, Davidoff S, Krevsky B, Fisher RS, Parkman HP. Whole gut transit scintigraphy in the clinical evaluation of patients with upper and lower gastrointestinal symptoms. Am J Gastroenterol 2000; 95 (10) 2838-2847
• 131 Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002; 16 (10) 1781-1790
• 132 Maqbool S, Parkman HP, Friedenberg FK. Wireless capsule motility: comparison of the SmartPill GI monitoring system with scintigraphy for measuring whole gut transit. Dig Dis Sci 2009; 54 (10) 2167-2174
• 133 Parkman HP. Assessment of gastric emptying and small-bowel motility: scintigraphy, breath tests, manometry, and SmartPill. Gastrointest Endosc Clin N Am 2009; 19 (01) 49-55 , vi
• 134 Diaz Tartera HO, Webb DL, Al-Saffar AK. et al. Validation of SmartPill^® wireless motility capsule for gastrointestinal transit time: Intra-subject variability, software accuracy and comparison with video capsule endoscopy. Neurogastroenterol Motil 2017; 29 (10) 1-9
• 135 Southwell BR, Clarke MC, Sutcliffe J, Hutson JM. Colonic transit studies: normal values for adults and children with comparison of radiological and scintigraphic methods. Pediatr Surg Int 2009; 25 (07) 559-572
• 136 Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991; 6 (02) 151-156
• 137 Cersosimo MG, Raina GB, Pecci C. et al. Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. J Neurol 2013; 260 (05) 1332-1338
• 138 Halawi HM, Maasri KA, Mourad FH, Barada KA. Faecal impaction: in-hospital complications and their predictors in a retrospective study on 130 patients. Colorectal Dis 2012; 14 (02) 231-236
• 139 Kim JS, Sung HY, Lee KS, Kim YI, Kim HT. Anorectal dysfunctions in Parkinson's disease. J Neurol Sci 2011; 310 (1-2): 144-15
• 140 Yu T, Wang Y, Wu G, Xu Q, Tang Y, Lin L. High-resolution anorectal manometry in Parkinson Disease With Defecation Disorder: A Comparison With Functional Defecation Disorder. J Clin Gastroenterol 2016; 50 (07) 566-571
• 141 Horsager J, Andersen KB, Knudsen K. et al. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. Brain 2020; 143 (10) 3077-3088
• 142 Voderholzer WA, Schatke W, Mühldorfer BE, Klauser AG, Birkner B, Müller-Lissner SA. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol 1997; 92 (01) 95-98
• 143 Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 2006; 130 (03) 657-664
• 144 Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum 2007; 50 (04) 428-441
• 145 Bharucha AE, Wald A. Chronic constipation. Mayo Clin Proc 2019; 94 (11) 2340-2357
• 146 Law NM, Bharucha AE, Zinsmeister AR. Rectal and colonic distension elicit viscerovisceral reflexes in humans. Am J Physiol Gastrointest Liver Physiol 2002; 283 (02) G384-G389
• 147 Bae HJ, Cheon SM, Kim JW. Autonomic dysfunctions in parkinsonian disorders. J Mov Disord 2009; 2 (02) 72-77
• 148 Ou R, Song W, Wei Q. et al. Characteristics of nonmotor symptoms in progressive supranuclear palsy. Parkinsons Dis 2016; 2016: 9730319
• 149 Radicati FG, Martinez Martin P, Fossati C. et al. Non motor symptoms in progressive supranuclear palsy: prevalence and severity. NPJ Parkinsons Dis 2017; 3: 35
• 150 Baschieri F, Vitiello M, Cortelli P, Calandra-Buonaura G, Morgante F. Autonomic dysfunction in progressive supranuclear palsy. J Neurol 2023; 270 (01) 109-129
• 151 Colosimo C, Morgante L, Antonini A. et al; PRIAMO STUDY GROUP. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol 2010; 257 (01) 5-14
• 152 Alfonsi E, Versino M, Merlo IM. et al. Electrophysiologic patterns of oral-pharyngeal swallowing in parkinsonian syndromes. Neurology 2007; 68 (08) 583-589
• 153 Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2017; 88 (05) 402-411
• 154 Johnston BT, Castell JA, Stumacher S. et al. Comparison of swallowing function in Parkinson's disease and progressive supranuclear palsy. Mov Disord 1997; 12 (03) 322-327
• 155 Oliveira MCB, Ling H, Lees AJ, Holton JL, De Pablo-Fernandez E, Warner TT. Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2019; 90 (05) 555-561
• 156 Valldeoriola F, Valls-Solé J, Tolosa ES, Marti MJ. Striated anal sphincter denervation in patients with progressive supranuclear palsy. Mov Disord 1995; 10 (05) 550-555
• 157 Winge K, Jennum P, Lokkegaard A, Werdelin L. Anal sphincter EMG in the diagnosis of parkinsonian syndromes. Acta Neurol Scand 2010; 121 (03) 198-203
• 158 Wenning GK, Stankovic I, Vignatelli L. et al. The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord 2022; 37 (06) 1131-1148
• 159 Roncevic D, Palma JA, Martinez J, Goulding N, Norcliffe-Kaufmann L, Kaufmann H. Cerebellar and parkinsonian phenotypes in multiple system atrophy: similarities, differences and survival. J Neural Transm (Vienna) 2014; 121 (05) 507-512
• 160 Wenning GK, Geser F, Krismer F. et al; European Multiple System Atrophy Study Group. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013; 12 (03) 264-274
• 161 Jung YJ, Kim HJ, Yoo D. et al. Various motor and non-motor symptoms in early multiple system atrophy. Neurodegener Dis 2019; 19 (5-6): 238-243
• 162 Do HJ, Seo HG, Lee HH. et al. Progression of oropharyngeal dysphagia in patients with multiple system atrophy. Dysphagia 2020; 35 (01) 24-31
• 163 Iwasaki S, Narabayashi Y, Hamaguchi K, Iwasaki A, Takakusagi M. Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage. J Neurol 1990; 237 (02) 77-79
• 164 Tezuka T, Ozawa T, Takado Y, Sato Y, Oyake M, Nishizawa M. Megacolon in multiple system atrophy: safety concerns related to PEG. Mov Disord 2009; 24 (07) 1096-1097
• 165 Tanaka Y, Kato T, Nishida H. et al. Is there delayed gastric emptying in patients with multiple system atrophy? An analysis using the (13)C-acetate breath test. J Neurol 2012; 259 (07) 1448-1452
• 166 Köllensperger M, Geser F, Ndayisaba JP. et al; EMSA-SG. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010; 25 (15) 2604-2612
• 167 Sakakibara R, Odaka T, Uchiyama T. et al. Colonic transit time, sphincter EMG, and rectoanal videomanometry in multiple system atrophy. Mov Disord 2004; 19 (08) 924-929
• 168 Jellinger KA. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies. J Neural Transm (Vienna) 2018; 125 (04) 615-650
• 169 Larsson V, Torisson G, Bülow M, Londos E. Effects of carbonated liquid on swallowing dysfunction in dementia with Lewy bodies and Parkinson's disease dementia. Clin Interv Aging 2017; 12: 1215-1222
• 170 Taylor JP, McKeith IG, Burn DJ. et al. New evidence on the management of Lewy body dementia. Lancet Neurol 2020; 19 (02) 157-169
• 171 Doi H, Sakakibara R, Masuda M. et al. Gastrointestinal function in dementia with Lewy bodies: a comparison with Parkinson disease. Clin Auton Res 2019; 29 (06) 633-638
• 172 Goetz CG, Tilley BC, Shaftman SR. et al; Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23 (15) 2129-2170
• 173 Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, de Pedro-Cuesta J, Martinez-Martin P. Longitudinal Parkinson's Disease Patient Study, Estudio Longitudinal de Pacients con Enfermedad da Parkinson Group. Independent validation of the scales for outcomes in Parkinson's disease-autonomic (SCOPA-AUT). Eur J Neurol 2010; 17 (02) 194-201
• 174 van Wamelen DJ, Martinez-Martin P, Weintraub D. et al; International Parkinson and Movement Disorder Society Parkinson's Disease Non-Motor Study Group. The non-motor symptoms scale in Parkinson's disease: validation and use. Acta Neurol Scand 2021; 143 (01) 3-12
• 175 Perez Lloret S, Pirán Arce G, Rossi M, Caivano Nemet ML, Salsamendi P, Merello M. Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease. Mov Disord 2007; 22 (01) 107-111
• 176 Camacho M, Greenland JC, Williams-Gray CH. The gastrointestinal dysfunction scale for Parkinson's disease. Mov Disord 2021; 36 (10) 2358-2366
• 177 Austin KVD, Norris V, Wan W, Cloud L. Further validation of a scale to measure gastrointestinal symptoms in Parkinson's disease. presented at: Thirtieth Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders; September 19, 2016 2016; Portland, Oregon
• 178 Manor Y, Giladi N, Cohen A, Fliss DM, Cohen JT. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson's disease. Mov Disord 2007; 22 (13) 1917-1921